Safe, effective, and scalable vaccines and therapeutics are needed to halt the ongoing SARS-CoV-2 pandemic. The receptor-binding domain (RBD) is immunodominant and the target of 90% of the neutralizing activity present in SARS-CoV-2 convlescent sera. To further understand this point, we structurally defined an RBD antigenic map using cryo-electron microscopy, ELISA, and BLI.